Engineering mRNA Vaccines for Broad Coronavirus Protection: Insights from RBD-Swapped Antigen Design

Study Background and Research Question

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the related SARS-CoV have posed substantial threats to global health, with the COVID-19 pandemic and earlier SARS outbreak demonstrating the rapid impact of evolving coronaviruses. The principal challenge in developing effective vaccines lies in the frequent mutations observed in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, particularly in the Omicron variant, which can significantly undermine the efficacy of existing vaccines (Guan et al., 2024). The central research question in this work was whether an mRNA vaccine engineered to present a conserved RBD—specifically, by replacing the highly mutable Omicron RBD with the more conserved SARS-CoV RBD—could elicit broad and potent immune protection against both SARS-CoV-2 variants and SARS-CoV.

Key Innovation from the Reference Study

The study by Guan and colleagues introduces a unique antigen design strategy for mRNA vaccines: deletion of the Omicron RBD or its replacement with the conserved SARS-CoV RBD in the spike (S) protein sequence. This approach is intended to circumvent the problem of variant-specific immune escape by leveraging the cross-reactivity and immunogenicity of the SARS-CoV RBD, which exhibits higher sequence conservation among related coronaviruses. The resulting mRNA constructs, encapsulated in lipid nanoparticles (LNPs), are designed to induce immunity that is both cross-protective and resilient to future RBD mutations (Guan et al., 2024).

Methods and Experimental Design Insights

The researchers constructed two LNP-encapsulated mRNA vaccines based on the SARS-CoV-2 spike protein: one with the mutant Omicron RBD deleted (SARS2-S (RBD-del)), and another with the Omicron RBD replaced by the SARS-CoV RBD (SARS2-S (SARS-RBD)). mRNA was produced via in vitro transcription, purified, and encapsulated into LNPs for in vivo administration. The stability of the mRNA-LNP formulations was assessed at various temperatures, and their immunogenicity was evaluated in mouse models.

Immunological readouts included measurement of T-cell responses, antibody titers specific to S and RBD proteins, neutralization assays with pseudotyped viruses, and challenge studies with infectious SARS-CoV-2 Omicron and SARS-CoV in mice. Protective efficacy was quantified by reductions in viral titers in lung tissues, prevention of weight loss, and survival outcomes following viral challenge (Guan et al., 2024).

Protocol Parameters

• assay | in vitro transcription (IVT) | 37°C, 2-4 h | applicable for mRNA vaccine synthesis with pseudouridine modification | optimal for high-yield RNA with modified nucleotides | workflow_recommendation
• assay | mRNA-LNP storage | 4°C, up to 7 days; -80°C, >1 month | applicable for stability studies and vaccine stockpiling | preserves mRNA integrity and LNP structure | paper
• assay | mouse immunization | 10 μg mRNA per dose, intramuscular | applicable for preclinical vaccine immunogenicity | standard dose for murine mRNA vaccine testing | paper
• assay | pseudovirus neutralization | serial serum dilutions | applicable for cross-neutralization studies | quantifies breadth and potency of antibody response | paper
• assay | challenge infection | 10⁴-10⁵ PFU virus | applicable for protection efficacy models | ensures measurable infection without overwhelming host | paper
• assay | RNA modification (pseudo-uridine) | 100% substitution for UTP | applicable for reducing innate immunogenicity and enhancing RNA stability in mRNA synthesis | improves translation, persistence, and immune profile of RNA | internal_article

Core Findings and Why They Matter

Among the two vaccine constructs, the SARS2-S (SARS-RBD) mRNA vaccine demonstrated superior immunological breadth and potency. Key findings include:

• Strong induction of both T-cell responses and antibodies specific to the S and RBD proteins of both SARS-CoV-2 and SARS-CoV.
• Potent neutralization of pseudotyped viruses representing both SARS-CoV-2 Omicron and SARS-CoV.
• Significant reduction in viral titers in the lungs of immunized mice following Omicron challenge, and complete protection from SARS-CoV-induced weight loss and mortality (Guan et al., 2024).
• Passive transfer of serum from vaccinated mice conferred protection in naïve mice, with protective efficacy correlating with neutralizing antibody titers.

These results are particularly important for the future of mRNA vaccine development, suggesting that antigen engineering—specifically using a conserved RBD—can yield vaccines with broader and more durable protection, potentially applicable to emerging and future coronavirus threats.

Comparison with Existing Internal Articles

Several internal resources elaborate on the technical and translational significance of pseudo-modified uridine triphosphate (Pseudo-UTP) in mRNA synthesis:

• Pseudo-modified Uridine Triphosphate: Driving mRNA Synthesis highlights that Pseudo-UTP incorporation enhances RNA stability and reduces immunogenicity, key for robust mRNA vaccine performance. This aligns with the rationale for using modified nucleotides in the reference study, though the paper focuses on antigen design rather than nucleotide chemistry.
• Strategic Leverage of Pseudo-UTP discusses how modified nucleotides like Pseudo-UTP contribute to increased persistence and translation efficiency in RNA therapeutics, supporting the translational potential of the mRNA-LNP platform used by Guan et al.
• The internal article Mechanistic Implications of Pseudo-UTP further bridges the gap between molecular modification and clinical translation, which complements the reference study's focus on immunogenicity outcomes and vaccine breadth.

While the reference study centers on antigen design to overcome variant-specific immune escape, internal articles provide complementary mechanistic insights into how RNA modifications, such as Pseudo-UTP, can optimize the underlying mRNA for vaccine and gene therapy applications.

Limitations and Transferability

The primary limitation of the study is its preclinical focus: efficacy and immunogenicity were demonstrated in murine models, which may not fully predict immune responses or protection in humans. Additionally, the specific antigen design—while promising for coronaviruses with shared RBD features—may not universally apply to all emerging variants or distantly related coronaviruses. The work does not directly address manufacturing, scale-up, or regulatory challenges related to the clinical translation of such broadly-protective mRNA vaccines (Guan et al., 2024).

Regarding transferability, the antigen-engineering approach is broadly applicable within the coronavirus family but will require further validation across species and in human clinical trials. Incorporation of pseudo-modified nucleotides, as discussed in internal sources, is already established as a best practice for enhancing RNA stability and reducing innate immune sensing in both preclinical and clinical mRNA vaccine workflows (internal_article).

Why this cross-domain matters, maturity, and limitations

The convergence of antigen engineering (targeting conserved viral elements) and advanced RNA chemistry (pseudo-modified nucleotides) represents a critical maturation point for next-generation mRNA vaccines. The referenced study demonstrates cross-variant protection within the coronavirus domain, but its findings cannot be extrapolated to unrelated viral families without further evidence. Nevertheless, the integration of these two scientific domains—antigen design and RNA modification—offers a robust platform for rapid pandemic response and universal vaccine development, provided that clinical translation and regulatory hurdles are addressed (Guan et al., 2024; internal_article).

Research Support Resources

For researchers seeking to replicate or extend similar mRNA vaccine workflows incorporating pseudouridine modification, Pseudo-UTP (SKU B7972) from APExBIO offers a high-purity, ready-to-use pseudo-modified uridine triphosphate for in vitro transcription applications. The use of Pseudo-UTP is well-established for enhancing RNA stability, translation efficiency, and minimizing innate immune activation—key factors in both vaccine and gene therapy RNA design (internal_article). For detailed guidance on integration into RNA synthesis protocols, refer to the cited internal resources above. Pseudo-UTP and related workflow solutions are intended strictly for research use.